Disease Landscape and Forecast Insights
Comprehensive market intelligence and actionable insights help you optimize your long-term disease strategy
Schizophrenia | Unmet Need | Cognitive Impairment Associated with Schizophrenia | US/EU | 2016
Decision Resources Group (DRG) estimates that 80% of the more than 3 million diagnosed prevalent cases of schizophrenia within our surveyed markets (i.e., United States, France, Germany, and United…
Multiple Sclerosis | Unmet Need | Relapsing Remitting Multiple Sclerosis | US/EU | 2016
An increasing number of clinically unique disease-modifying therapies (DMTs) have been approved for the treatment of relapsing-remitting multiple sclerosis (RR-MS), the most prevalent form of MS…
Colorectal Cancer | Access and Reimbursement | Optimal Sequencing of Angiogenesis and EGFR Inhibitors in Colorectal Cancer | US | 2016
Seven premium-priced therapies—Avastin, Erbitux, Vectibix, Zaltrap, Stivarga, Lonsurf, and Cyramza—are approved in the United States for metastatic colorectal cancer. Therefore, medical…